Diffuse large B cell lymphoma (DLBCL). Diffuse non-Hodgkin's lymphoma, Large cell (diffuse)
Conditions
Interventions
Intervention 1: Mabthera (375 mg/m2) every 3 weeks for 6 months (8 courses). Intervention 2: Reditux (375 mg/m2) every 3 weeks for 6 months (8 courses).
Treatment - Drugs
Mabthera (375 mg/m2) every 3 weeks for 6 months (8 courses)
Reditux (375 mg/m2) every 3 weeks for 6 months (8 courses)
Sponsors
Cinnagen Company
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: DLBCL patients 18 to 65 years old (male & female); CD 20 marker positivity; Completion of informal consent. Exclusion criteria: Recurrence DLBCL; Systolic dysfunction (EF3; Advanced Liver or renal dysfunctions (Bil T >6 mg/dl or Cr >4 mg/dl).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiographic response rate. Timepoint: At the end of quarter and end of treatment. Method of measurement: Radiography ( CT–Scan/ MRI ). | — |
Secondary
| Measure | Time frame |
|---|---|
| Hematologic response rate, Partial remission and Complete remission. Timepoint: Three weeks (end of treatment), hematologic evaluation is done and the next course of treatment is started. And at the end of the fourth and eighth radiologic evaluation occurs. Method of measurement: The variables measured in blood; through the blood and bone marrow radiological assessment if necessary. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Sina Salari
Taleghani Hospital, Shahid Beheshti University of Medical Sciences
Outcome results
None listed